To further validate our approach, we carried out western blot for KRAS using an anti-panKRAS antibody (this antibody captures KRAS without discerning the isoform of the KRAS protein) in seven selected patient samples (5 NSCLC (lanes 2–5, 7), one pancreatic cancer (lane 6) and one healthy control (lane 8) where we had previously identified the WT KRAS by LC-SRM. Here, KRAS is linked to non-small cell lung carcinoma.